Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: April 1, 2023

Details for Patent: 7,700,645

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions

Which drugs does patent 7,700,645 protect, and when does it expire?

Patent 7,700,645 protects SYMTUZA, PREZISTA, and PREZCOBIX, and is included in four NDAs.

Protection for PREZISTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in twenty-five countries.

Summary for Patent: 7,700,645
Title:Pseudopolymorphic forms of a HIV protease inhibitor
Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sul- fonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
Inventor(s): Vermeersch; Hans Wim Pieter (Ghent, BE), Thone; Daniel Joseph Christiaan (Beerse, BE), Janssens; Luc Donne Marie-Louise (Malle, BE)
Assignee: Tibotec Pharmaceuticals Ltd. (Little Island, Co. Cork, IE)
Application Number:10/514,352
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,700,645
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,700,645

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Prods SYMTUZA cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 210455-001 Jul 17, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Janssen Prods PREZISTA darunavir SUSPENSION;ORAL 202895-001 Dec 16, 2011 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Janssen Prods PREZCOBIX cobicistat; darunavir TABLET;ORAL 205395-001 Jan 29, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,700,645

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02076929May 16, 2002
PCT Information
PCT FiledMay 16, 2003PCT Application Number:PCT/EP03/50176
PCT Publication Date:December 24, 2003PCT Publication Number: WO03/106461

International Family Members for US Patent 7,700,645

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2052 ⤷  Sign Up
Australia 2003271740 ⤷  Sign Up
Australia 2012205289 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.